Literature DB >> 9354653

Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.

M Casato1, V Agnello, L P Pucillo, G B Knight, M Leoni, S Del Vecchio, C Mazzilli, G Antonelli, L Bonomo.   

Abstract

We have prospectively studied patients with type II cryoglobulinemia since 1985 to assess the efficacy of treatment with interferon-alpha at cumulative doses ranging from 234 to 849 MU. In the present study we retrospectively evaluated in this cohort parameters associated with complete response to therapy in 31 consecutive patients with type II cryoglobulinemia associated with hepatitis C virus (HCV) infection. Prevalence of complete response of cryoglobulinemia (disappearance of symptoms and signs of vasculitis and decrease of cryocrit below 10% of the initial value) was 62%, with a median response duration of 33 months and a range of 3 to 100 months. Three patients were putatively cured, as they remained in complete remission for more than 5 years off therapy. Eighteen patients (58%) had liver disease evidenced by histopathology and/or raised transaminase levels. Prevalence of normalization of transaminase levels was 100%, with a median response duration of 36 months. Relapse of hypertransaminasemia occurred in 100% and 8% of patients receiving less than or greater than 621 MU, respectively. By logistic regression analysis, the only pretherapy parameter that associated significantly (P = .0393) with complete response of cryoglobulinemia was the solitary anti-C22 (HCV core) antibody pattern, which was observed in 29% of patients. Association with older age and low cryocrit approached statistical significance (P = . 06), while no significant correlations were found with serum IgM levels, duration of disease, HCV genotype, NS5a gene mutations, liver histology, HLA-DR phenotype, or WA cross-idiotype. Complete responses were also associated, on univariate statistical analysis, with low pretherapy HCV viremia. Responses were accompanied by decrease of viremia, of anti-HCV antibody levels and cryocrit. The usefulness of a high dose regimen is underscored by the higher rates of sustained responses of cryoglobulinemia and transaminase levels compared with previous studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354653

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Hepatitis C virus infection and lymphoproliferative disorders.

Authors:  L R Peña; S Nand; N De Maria; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

2.  Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.

Authors:  Emilio D'Amico; Caterina Chincoli; Pierluigi Cacciatore; Gabriella di Pasqua; Luana Cosentino; Giuseppe Riario-Sforza; Ernesta Pennese; Fabio Capani; Carlo Palazzi
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

3.  Hepatitis C- and human immunodeficiency virus-induced hypersensitivity vasculitis: a clinical pathology conference held by the division of rheumatology at hospital for special surgery.

Authors:  Roodabeh Michelle Koolaee; Ora Singer; Anne Bass; Robert Winchester; Surya Seshan; Doruk Erkan
Journal:  HSS J       Date:  2009-11-17

Review 4.  Hepatitis C and kidney disease: An overview and approach to management.

Authors:  Ahmad Najib Azmi; Soek-Siam Tan; Rosmawati Mohamed
Journal:  World J Hepatol       Date:  2015-01-27

5.  Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus.

Authors:  P Cresta; L Musset; P Cacoub; L Frangeul; D Vitour; T Poynard; P Opolon; D T Nguyen; F Golliot; J C Piette; J M Huraux; F Lunel
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 6.  Hepatitis C virus-associated extrahepatic manifestations: a review.

Authors:  Damien Sène; Nicolas Limal; Patrice Cacoub
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 7.  Hepatitis C virus-induced cryoglobulinemia.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  Kidney Int       Date:  2009-07-15       Impact factor: 10.612

Review 8.  Hepatitis C virus-related lymphoproliferative disorders: an overview.

Authors:  Anna-Linda Zignego; Carlo Giannini; Clodoveo Ferri
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 9.  Hepatitis C virus infection induced vasculitis.

Authors:  Patrice Cacoub; David Saadoun
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

10.  Successful combination of Rituximab and plasma exchange in the treatment of cryoglobulinemic vasculitis with skin ulcers: a case report.

Authors:  Tiziano Tallarita; Massimiliano Gagliano; Daniela Corona; Giuseppe Giuffrida; Alessia Giaquinta; Domenico Zerbo; Massimiliano Sorbello; Pierfrancesco Veroux; Massimiliano Veroux
Journal:  Cases J       Date:  2009-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.